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immunosuppression do remain. But, instead of consid-
ering why facial transplantation cannot be justified, we
may find it hard to justify why it should not be done.
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Extra scrutiny for industry funded trials
JAMA’s demand for an additional hurdle is unfair—and absurd
Suppose that a biomedical journal invoked anew policy requiring that all authors based inwestern Europe or North America would
receive ordinary peer review, but authors from other
countries would receive a peer review with additional
hurdles. This policy may seem unfair, but suppose
the journal claimed that research has shown that there
is a greater prevalence of fraud, bias, and sloppy
work among papers coming from these other
countries.
If these events actually transpired, we hope that
other biomedical journals would rapidly point out that
adopting such a policy would be unfair to authors
from non-western countries, even if the premises for it
were valid. Indeed, we hope that other editors would
decide that it would be unethical to create any hierar-
chical system for submissions of papers to a biomedi-
cal journal. Peer review ought to rest on the content of
a submission rather than solely on the basis of
presumptions inferred from group affiliation such as
nationality.
We would hope so, but we are not sure. A logically
similar situation has actually occurred, with a few small
differences from the above scenario. The new
instructions for authors at JAMA include the
following1 2:
For reports containing original data, at least 1 author
(eg, the principal investigator) who is independent of any
commercial funder should indicate that she or he ‘had full
access to all the data in the study and takes responsibility for
the integrity of the data and the accuracy of the data analy-
sis.’ For industry-sponsored studies, the data analysis should
be conducted bystatisticians at an academic center, rather
than only by statisticians employed by the company
sponsoring the research.
The additional hurdle for research submissions
with industry funding comes before peer review, and
requires authors to hire an academic statistician before
their submission will be considered by JAMA. Other
submitters need not be concerned about this
requirement.
This policy is manifestly unfair. It violates the
proposition that each submission should be consid-
ered on its merits and it creates a hierarchy of purity
among authors. We presume that the intent is well
motivated, in the sense that the editors at JAMA have
recognised the potential for a problem—perhaps bias,
fraud, or shoddy work—in submissions funded by
industry. JAMA’s draconian solution, however, punishes
the innocent along with the guilty, and denigrates the
reliability and professionalism of industry-employed
statisticians, whose credentials JAMA apparently
considers insufficient.
Following these new instructions raises many ques-
tions that require arbitrary distinctions. The instruc-
tions require an academic statistician either to conduct
or to bless the analysis. But what is the mark of a quali-
fied statistician? A degree? Certification by the Royal
Statistical Society? And who is academic? A retired
professor who becomes an industry consultant? A
retired industry statistician who joins a university?
Once paid by industry, would an academic statistician
remain independent? Will mail order universities be
acceptable, or must the universities meet specific
accreditation requirements?
These questions are meant only to illuminate the
absurdity introduced by these new instructions. We
suspect that if the new rule were to spread to other
journals there would soon be a thriving cottage indus-
try among “academic statisticians” to vet analyses from
the private sector, along the lines of professional
expert witnesses in tort cases. Even if the rules could be
clearly and cogently stated, they would be objection-
able simply because it is unfair to judge work solely on
the basis of affiliation of the authors.3 We recognise that
there is growing and legitimate concern about the
methods used by commercial enterprises to influence
publication and consequently the public perception of
their products.4 Even so, as Smith says, “The companies
seem to get the results they want not by fiddling the
results, which would be far too crude and possibly
detectable by peer review, but rather by asking the
‘right’ questions—and there are many ways to do this.”4
The broader problem will need imaginative solutions,
not an attempt to police the work of industry funded
statisticians as JAMA has proposed. The decision to
publish should be based on content, and the process
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should be the same for all submissions regardless of
country of origin or type of institution.
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Sharing the benefits of genetic research
Will the World Trade Organization act to stop the exploitation of biodiversity?
Campaigners are calling on policy makers atnext week’s sixth World Trade Organizationministerial conference in Hong Kong to make
trade fairer for and improve the lives and health of the
world’s poorest people. This broad and important aim
may dominate the headlines, but ministers will also be
discussing technical issues surrounding international
patenting laws. One issue with implications for the
development of medical products is the tension
between international patenting laws and benefit shar-
ing requirements, which may threaten agreements on
protecting biodiversity. If the biodiversity door shuts
because of protests in developing countries, pharma-
ceutical research will be seriously hampered.
In Hong Kong the World Trade Organization can
stop the exploitation of non-human genetic material
and traditional knowledge by aligning the trade related
intellectual property rights (TRIPS) agreement with
the Convention on Biological Diversity. Over the past
decade benefit sharing has become a recurrent theme
in international debates on human and non-human
genetics. The term arose from the Convention on Bio-
logical Diversity adopted at the 1992 earth summit in
Rio de Janeiro, Brazil.1 The convention has three
objectives: the conservation of biological diversity, the
sustainable use of its components, and the fair and
equitable sharing of benefits from the use of genetic
resources (“benefit sharing”). Although benefit sharing
is compulsory when the biosciences industry or
research centres use biodiversity and associated local
or indigenous knowledge to develop new products and
services, it is not covered by legally binding
international trade agreements, such as TRIPS,2 nor
does it cover human genetic resources.
Benefit sharing is particularly important in three
contexts in genetics: access to non-human genetic
resources and associated traditional knowledge, human
genetic banking, and research on rare genotypes.3 The
few benefit sharing agreements that have been signed
to date have been widely criticised (see box on
bmj.com).4–7
Concerns regarding benefit sharing for non-human
genetic resources and traditional knowledge have
included practical problems such as: how can prior
informed consent be obtained from large communities
without adequate means of representation; how can the
socioeducational gap between negotiating partners be
bridged; how can lack of trust between negotiating
partners be overcome; and which benefits should be
made available when and to whom? Principled
objections have included concerns about incompatibility
between the concept of communally owned traditional
knowledge and the intellectual property rights system;
views that sacred knowledge ought never be patented;
and the fear that benefiting individual communities
according to ethnic distinctions is divisive.
These concerns should not detract from the fact
that 187 countries and the European Union have
agreed in the Convention on Biological Diversity that
benefit sharing for non-human genetic resources and
traditional knowledge is legally binding.1 It is in this
context that an earlier ministerial conference of World
Trade Organization members agreed the Doha
Mandate in Qatar in November 2001.8 This mandate
identified the need for further negotiation on the clash
between TRIPS and the Convention on Biological
Diversity. This was reinforced by a series of submissions
to theWorld Trade Organization from a group of Latin
American and Asian countries which suggested how to
bridge the gap between the two agreements.9 These
submissions urged that patent applicants should
provide disclosure of the source and country of origin
of the biological resource and of the traditional knowl-
edge used in the invention; evidence of prior informed
consent through approval of authorities under the rel-
evant national regime; and evidence of fair and equita-
ble benefit sharing under the relevant national regime.
Without the proposed revision of TRIPS, the Con-
vention on Biological Diversity is legally binding but
lacks “teeth” because it does not include the strong
mechanism for dispute settlement that is provided by
World Trade Organization treaties. Ministers will
consider the revision in Hong Kong and are in an
excellent position to stop the exploitation of non-
human genetic resources and traditional knowledge.
Aside from the discussions in Hong Kong, benefit
sharing for human genetic resources is an even greater
challenge, as none of the relevant international guide-
lines are legally binding (HUGO Ethics Committee
statement on benefit sharing,10 UNESCO International
Declaration on Human Genetic Data11). It has therefore
been suggested that the Convention on Biological
Diversity should be extended to include human genetic
Box showing benefit sharing agreements is on bmj.com
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